The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PAHC | +87.62% | +170.97% | +22.06% | +232% |
| S&P | +13.66% | +87.02% | +13.34% | +267% |
Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment consists of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.
The company's shares have been slipping since it announced fiscal 2023 fourth-quarter earnings.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $363.89M | 39.7% |
| Gross Profit | $119.35M | 52.1% |
| Gross Margin | 32.80% | 2.7% |
| Market Cap | $1.64B | 79.8% |
| Market Cap / Employee | $0.66M | 0.0% |
| Employees | 2.5K | 27.6% |
| Net Income | $26.53M | 280.3% |
| EBITDA | $60.72M | 132.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $72.77M | 40.4% |
| Accounts Receivable | $217.90M | 35.5% |
| Inventory | 471.8 | 73.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $757.63M | 52.6% |
| Short Term Debt | $27.47M | 78.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.77% | 4.0% |
| Return On Invested Capital | 4.92% | -0.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.50M | -248.2% |
| Operating Free Cash Flow | $9.30M | -26.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 44.12 | 27.33 | 21.53 | 24.33 | -53.63% |
| Price to Book | 3.29 | 3.51 | 3.89 | 5.74 | 62.71% |
| Price to Sales | 0.77 | 0.73 | 0.80 | 1.18 | 35.34% |
| Price to Tangible Book Value | 5.28 | 5.68 | 5.96 | 8.65 | 52.71% |
| Price to Free Cash Flow TTM | 43.05 | 29.36 | 46.44 | 111.49 | 340.69% |
| Enterprise Value to EBITDA | 36.01 | 30.70 | 37.55 | 38.76 | -24.37% |
| Free Cash Flow Yield | 2.3% | 3.4% | 2.2% | 0.9% | -77.31% |
| Return on Equity | 7.5% | 11.9% | 17.8% | 23.8% | 263.23% |
| Total Debt | $789.46M | $770.02M | $761.55M | $785.10M | 53.37% |
No podcast episodes available.
PAHC earnings call for the period ending September 30, 2021.
PAHC earnings call for the period ending June 30, 2021.
PAHC earnings call for the period ending March 31, 2021.
PAHC earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
